FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY 2
Clinical trials for FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY 2 explained in plain language.
Never miss a new study
Get alerted when new FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY 2 trials appear
Sign up with your email to follow new studies for FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY 2, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Breakthrough drug trial offers hope for rare muscle disease
Disease control Recruiting nowThis study is testing an experimental drug called AOC 1020 for people with facioscapulohumeral muscular dystrophy (FSHD), a genetic condition that causes progressive muscle weakness. About 200 participants will receive either the drug or a placebo via IV infusion every six weeks …
Matched conditions: FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY 2
Phase: PHASE3 • Sponsor: Avidity Biosciences, Inc. • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC
-
Patients unite to power FSHD research through new national registry
Knowledge-focused Recruiting nowBetterLife FSHD is a patient-driven registry and online platform for people with Facioscapulohumeral Muscular Dystrophy (FSHD). It aims to collect health and experience data from up to 5,000 participants through regular surveys to help researchers better understand the disease. T…
Matched conditions: FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY 2
Sponsor: FSHD Society • Aim: Knowledge-focused
Last updated Mar 13, 2026 15:06 UTC